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Background. Screening for type 2 diabetes is recommended in at-risk patients. The GP’s elec-
tronic medical record (EMR) might be an attractive tool for identifying them.
Objective. To assess the value of the GP’s EMR in identifying patients at risk for undiagnosed
type 2 diabetes and the feasibility to use this information in usual care to initiate screening.
Methods. In 11 Dutch general practices (25 GPs), we performed an EMR-derived risk assess-
ment in all patients aged >45 and <75 years, without known diabetes, identifying those at risk
according to the American Diabetes Association recommendations. Patients with an EMR-
derived risk or risk after additional risk assessment during regular consultation were invited
for capillary fasting plasma glucose (FPG) measurement.
Results. Of 13 581 patients, 3858 (28%) had an EMR-based risk (hypertension, cardiovascular
disease, lipid metabolism disorders and/or obesity). Additional risk assessment in those without
an EMR-based risk showed that in 51%, greater than one risk factor was present, mainly family
history (51.2%) and obesity (59%). Ninety per cent returned for the FPG measurement. In both
groups, we found patients with an FPG exceeding the cut point for diabetes (5.9% versus 4.1%).
Conclusions.With additional risk assessment during consultation, the GP’s EMR was valuable
in identifying patients at risk for undiagnosed type 2 diabetes. It was feasible to use this informa-
tion to initiate screening. At-risk patients were willing to take part in screening. Better registra-
tion of family history and obesity will improve the EMR as a tool for identifying at-risk
patients in opportunistic screening in general practice.
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Introduction
Main reason to urge for screening for type 2 diabetes
mellitus is the long preclinical period of diabetes.
One-third to half of all people with diabetes remain
undiagnosed for many years. In the mean time, compli-
cations already begin to develop.1 Starting treating
patients with type 2 diabetes at an earlier stage might
prevent or delay the development of complications.2
However, at this moment, no evidence is available for
the effectiveness of screening programmes in reducing
diabetes-related morbidity and mortality. There is also
little knowledge about the ethical, psychological, and
social consequences of both true and false screening
results, and there is no consensus on the applied
screening test and diagnostic cut off points.3,4
Notwithstanding these considerations, nowadays
screening for type 2 diabetes is encouraged. It is recom-
mended to perform screening in a subgroup of patients
at risk for undiagnosed type 2 diabetes.5–8 As screening
should also be a systematic and continuous process,3
opportunistic screening of such at-risk patients might
be an interesting screening method in general practice.
This involves screening of at-risk individuals during
usual care, who are seen by health care professionals
for reasons not related to the condition for which
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screening is offered.9 At-risk patients can be identified
using questionnaires or risk scores.10–12 A pragmatic
approach might be assessing risk using risk factors for
undiagnosed type 2 diabetes that are already registered
in the medical records of the GP.
Relevant medical informations like diagnoses, medi-
cation use and referrals are available in the GP’s med-
ical record system, nowadays often computerized. If
GPs are well trained and software is user-friendly, an
electronic medical record (EMR) can be accurate and
complete.13 The GP’s EMR might therefore be an at-
tractive, inviting tool for identifying at-risk patients in
opportunistic screening.
The aim of this study was to assess the value of the
GP’s EMR in identifying people at risk for undiag-
nosed type 2 diabetes and the feasibility to use this
information in usual care to initiate screening.
Methods
Patients and setting
Patients were recruited from 11 general practices (25
GPs) in the Netherlands: seven of these practices were
participating in the Academic Research Network of
the Department of General Practice of the Radboud
University Nijmegen Medical Centre, CMR/NMP,14
two in the Registration Network Family Practices of
the University Maastricht (RNH)15 and two practices
were related to the network of the VU University
Medical Center Amsterdam.16 All patients aged >45
and <75 years and not known with type 2 diabetes who
were listed with these practices were considered for the
study. Diabetes—both known and undiagnosed—was
defined as having a fasting plasma glucose (FPG)
>7.0 mmol/l on two different days in asymptomatic
patients or a single random plasma glucose >11.0
mmol/l in patients with diabetes-related symptoms.
Impaired fasting glucose (IFG) was classified as having
a single FPG value >6.0 and <7.0 mmol/l.17,18
All practices used the Promedico EMR software
(Promedico ICT Inc., Nieuwegein, the Netherlands).
Registration of diagnoses was based on the electronic
version of the International Classification of Primary
Care (ICPC codes).19 Prescribed medication was coded
according to the Anatomical Therapeutic Chemical
classification system (ATC codes).20 This study is part
of an opportunistic screening programme for type 2
diabetes in general practice—the Diabscreen study.
Methods
People were considered to be at risk for undiagnosed
type 2 diabetes when having one or more of the fol-
lowing diabetes risk factors, derived from the Ameri-
can Diabetes Association’s (ADA) recommendations
in screening for type 2 diabetes: a family history of di-
abetes (parent and/or brother and/or sister with diabe-
tes), hypertension, cardiovascular disease (myocardial
infarction, heart failure, atrial fibrillation, stroke, pe-
ripheral vascular disease), lipid metabolism disorders,
obesity [body mass index (BMI) >27] and a history of
gestational diabetes mellitus (GDM).6 We translated
these risk factors into a set of matching ICPC and
ATC codes (Table 1). Family history of diabetes and
a history of GDM were not consistently coded in the
EMR by the GPs and could therefore not be used in
this list. At the time of study, no medication was reg-
istered to treat obesity and therefore an ATC code
was not yet available. Almost all patients were Cauca-
sian, so ethnicity was in this study not used as a risk
factor. Having children with a birth weight more than
4000 g was left out as it was not registered. An EMR-
derived risk assessment was conducted to identify the
patients with ICPC and/or ATC codes mentioned in
TABLE 1 Selection codes matching diabetes risk factors
Diagnoses (ICPC codes) Medication (ATC codes)
Hypertension Elevated blood pressure (K85) Diuretics (C03)
Hypertension, complicated (K86) Beta blockers (C07)
Hypertension, uncomplicated (K87) Calcium channel blockers (C08)
Angiotensin-converting enzyme inhibitors (C09)
Angiotensin II receptor blockers (C09)
Cardiovascular disease Ischaemic heart disease with angina (K74) Anticoagulants (B01)
Acute myocardial infarction (K75) Platelet aggregation inhibitors (B01)
Ischaemic heart disease without angina (K76) Cardiac glycosides (C01)
Heart failure (K77) Antiarrhythmics (C01)
Atrial fibrillation/flutter (K78) Nitrates (C01)
Transient cerebral ischaemia (K89)
Stroke/cerebrovascular accident (K90)
Cerebrovascular disease (K91)
Atherosclerosis/peripheral vascular disease (K92)
Lipid metabolism disorders Lipid disorder (T93) Serum lipid reducing agents (C10)
Obesity Obesity (BMI >30 kg/m2) (T82) NA
Overweight (BMI 27–30 kg/m2) (T83)
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Table 1. For this purpose, we had developed soft-
ware that enabled us to extract ICPC and ATC infor-
mation of each patient from the practices’ EMR and
to analyse these data anonymously at the university
department.
When ATC but no ICPC codes for cardiovascular
disease and hypertension were present, the patients’
own GPs were asked to check clinical information in
the EMR. In case medication matching these codes
had been prescribed for other conditions than cardio-
vascular disease or hypertension, this was considered
not a diabetes risk factor.
The EMR-derived risk status (risk/no risk) was then
marked in the EMR with an alert to trigger GPs when
patients visited the practice for usual care during the
following year. GPs were asked to initiate FPG mea-
surement in at-risk patients. For patients without risk
factors, the GPs needed to verify the EMR risk profile
by checking and in case of missing data completing risk
factors coded in the EMR (hypertension, cardiovascu-
lar disease, lipid metabolism disorders and obesity) and
checking risk factors not coded in the EMR (family his-
tory of diabetes and a history of GDM). In case this
additional risk assessment revealed risk, the patient
was invited by the GP for FPG measurement similar to
patients with an EMR-derived risk. FPG measurement
was conducted in the patients’ own general practice by
their own practice assistant. In all participating prac-
tices, a Gluco Touch (LifeScan Beerse (Belgium;
LifeScan Benelux)) plasma calibrated capillary blood
glucose metre was used. Prior to the start of the study,
all metres were checked and adjusted if necessary by
its manufacturer. The practice assistants were trained
in using the metres. Patients with a screening FPG >6.0
mmol/l (the cut point for IFG as earlier defined) were
followed up for further diagnostic testing according to
the earlier described definition. The two-step screening
strategy we used is topic of a separate publication.
Statistical tests
Statistical analysis was performed using the chi-square
test for categorical data and the Student’s t-test or
Kruskal–Wallis test for means where appropriate.
Data were analysed by means of the SAS 8.0 software
package.
Results
In the 11 participating practices, 49 229 patients were
registered, of whom 14 457 were aged >45 and <75
years. In 876 (6%) patients, diabetes mellitus had al-
ready been diagnosed, leaving 13 581 patients for the
study (Fig. 1). EMR-derived risk assessment identified
3858 (28%) at-risk patients leaving 9723 (72%) pa-
tients without an EMR-derived risk. Characteristics of
patients with and without an EMR-derived risk and
patients already diagnosed with diabetes are shown in
Table 2. No significant difference in sex was found be-
tween the three groups. Patients with known diabetes
were older than patients with an EMR-derived risk
(mean age 61.4 versus 60.5 years), who in turn were
older than those without an EMR-derived risk (mean
age 60.5 versus 55.2 years). Younger patients were less
likely to be at risk than older patients. We found little
interpractice variation. For example, Table 2 shows lit-
tle interpractice variation concerning mean age.
EMR-derived risk
In the course of 1 year, the GPs succeeded in bringing
up and discussing screening during consultation in
2270 (59%) of the patients with an EMR-derived risk
(Fig. 1). Of them, 2081 (92%) could be included for
the study (reasons for exclusion mentioned in Fig. 1).
We found a risk factor prevalence of 42.4% for hyper-
tension, 25.6% for cardiovascular disease, 16.5% for
lipid metabolism disorders and 30.0% for obesity. All
2081 patients were invited for FPG measurement.
At risk after additional risk assessment
In 3363 (35%) of the patients without an EMR-
derived risk, screening was discussed during consulta-
tion (Fig. 1). Of them, 3196 (95%) could be included
for the study. Additional risk assessment showed that
in 1643 (51%), at least one risk factor for diabetes
was present. In particular, family history of diabetes
and obesity was found as a source of missing data
(prevalence after checking 51.2% (family history),
59.0% (obesity) and 1.0% (history of GDM). All 1643
patients at risk after additional risk assessment were
then invited for an FPG measurement.
FPG measurement
In total, 1886 patients with an EMR-derived risk
(91%) and 1449 patients at risk after additional risk
assessment (88%) returned for an FPG measurement.
See Figure 1 and Table 3. Patients of the first group
were more often male (44.2% versus 39.9%) and older
(mean age 60.3 versus 55.6 years) than patients of the
latter group. In both groups, we found patients with
an FPG exceeding the cut point for IFG (13.5% versus
9.6%) and diabetes (5.9% versus 4.1%). Patients with
an EMR-derived risk had a slightly higher mean FPG
(5.6 versus 5.4 mmol/l).
Discussion
Summary of main findings
Identifying people at risk for undiagnosed type 2 dia-
betes mellitus using the medical data stored in the
GP’s EMR could be achieved during daily routine
practice, without any further support, e.g. from trial
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nurses. Of the population aged >45 and <75 years
and not known with diabetes, 28% had an EMR-
derived risk. Of the remaining 72% without an EMR-
derived risk, 51% were also found to be at risk after
additional risk assessment during usual care. So, in to-
tal, about 65% of the study population were at risk.
The diabetes risk factors hypertension, cardiovascu-
lar disease and lipid metabolism disorders were well
FIGURE 1 Study design
TABLE 2 Baseline characteristics of the study subgroups and known diabetes mellitus
EMR-derived risk,
n = 3858
No EMR-derived risk,
n = 9723
Known diabetes mellitus,
n = 876
P
Sex (% male) 48.6 49.3 49.2 NS
Mean age, years (95% CI) 60.5 (60.2–60.8) 55.2 (55.0–55.3) 61.4 (60.9–61.9) <0.0001
Interpractice variation
in mean age (years)
57–63 52–57 57–64 —
45–55 years (%) 17.1 79.7 3.2 <0.0001
55–65 years (%) 31.3 61.0 7.7
65–75 years (%) 44.0 45.2 10.8
TABLE 3 Sex, mean age and mean FPG and percentage of patients with FPG values exceeding IFG or diabetes cut points (bold printed border in Fig. 1)
EMR-derived risk and FPG measured,
n = 1886
At risk after additional risk assessment and
FPG measured, n = 1449
P
Sex (% male) 44.2 39.9 <0.05
Mean age, years (95% CI) 60.3 (59.9–60.6) 55.6 (55.2–56.0) <0.0001
Mean FPG, mmol/l (95% CI) 5.6 (5.5–5.6) 5.4 (5.4–5.5) <0.001
FPG 6.1–7.0 mmol/l (%) 13.5 9.6 —
FPG > 7.0 mmol/l (%) 5.9 4.1 —
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registered in the EMR and could easily be retrieved.
Hypertension and cardiovascular disease accounted
for 62% of the number at risk. In particular, obesity
and a family history of diabetes were poorly regis-
tered, and were mainly retrieved with additional risk
assessment during consultation.
Although patients had to return in a fasting state for
the FPG measurement, they were highly willing to do
so. Ninety per cent of patients who were invited re-
turned for the measurement.
In both risk groups (EMR-derived and additional
risk assessment), we found patients with an FPG value
exceeding the cut point of both IFG and diabetes mel-
litus. Their mean FPG values were about equal. So,
EMR-derived and additional risk assessment followed
by screening in at-risk patients from both groups
seems worthwhile.
Strengths and limitations of the study
As mentioned earlier, screening should be performed
systematically and continuously. This important condi-
tion can be fulfilled if one uses the GP’s EMR com-
bined with an EMR generated alert, as applied in our
study. In order to include possible new at-risk patients,
identification and labelling of people at risk for undi-
agnosed type 2 diabetes should be repeated by run-
ning the EMR risk extraction software, for example
every 3 years.
In 1 year, the GP succeeded in bringing up and dis-
cussing screening during consultation in about 60% of
patients with an EMR-derived risk, and in 35% of
those without an EMR-derived risk. As this screening
method could be used continuously, it is estimated
that within a period of 3 years, all patients, especially
those at risk, would have visited their GP. This equals
the 3-year interval recommended by the ADA in
screening for type 2 diabetes. The higher enrolment
of patients for screening from the group identified by
the EMR might be caused by the fact that, especially
in the beginning of the study, GPs were focused on
screening within patients with risk factors registered
in the EMR. It may also indicate the user-friendliness
of such approach. Their risk was clear and discussing
screening took less time than additional risk assess-
ment as was done in the second group. Furthermore,
the fact that one or more risk factors were recorded
in the EMR reflected that co-morbidity was present.
Such patients usually visit the GP more often, increas-
ing the possibility to discuss the need for screening.
All participating general practices were related to
a university department of general practice, which
might have positively influenced adherence to proto-
col. Nevertheless, they were all standard community
practices with a population representative of the
Dutch population and a diabetes prevalence equal to
that in the Netherlands.14–16,21 And although we found
that some GPs recruited better than others, overall we
found little interpractice variation.
The fact that the Dutch system of primary care pro-
vides for universal access and continuity of patient
registration enabled us to use the GP’s EMR in a con-
tinuous screening programme. In countries with a dif-
ferent health care system, our screening approach
might therefore be less feasible.
Cross-checking of medication information by the
patients’ GPs was necessary to improve validation,
but was time consuming. When clinical information
(ICPC) in the future is more complete, this would not
be necessary anymore, as risk then can be reliably as-
sessed merely on the basis of clinical information.
To screen for type 2 diabetes, we used the FPG test
rather than the oral glucose tolerance test (OGTT).
The OGTT consists of an FPG and 2-hour plasma glu-
cose value and has been considered as the gold stan-
dard test in diagnosing diabetes. The FPG test is
nevertheless recommended for screening in clinical set-
tings as it is easier and faster to perform, more conve-
nient and acceptable to patients and less expensive.6,22
The portable glucose metres we used are user-friendly
and readily available in general practice. A potential set
back is their variability,23 and consequent risk of false-
positive and false-negative outcomes. This study was di-
rected at the analysis of identification of at-risk patients
and reviewed a single testing. The two-step approach, in
which patients with glucose levels above the threshold
were measured again, did address the problems of false
positives. To take care of false-negative results, the pro-
cedure must be repeated—something that is beyond the
scope of this paper, but feasible in daily care.
Comparison with existing literature
In literature, several methods for identifying at-risk
patients have been described. Smith et al.24 described
an opportunistic diabetes screening study performed
in general practice using a questionnaire presented to
patients while waiting to see their doctor. Participation
rate was also high (93%) and 43% had at least two
risk factors. If performed continuously or repeated
regularly, such a method might help improving quality
of the EMR in a continuous screening programme.
Greaves et al.25 showed that identifying patients with
type 2 diabetes and IFG using data stored in the GP’s
databases was feasible. Screening of patients with
a BMI >27 and aged >50 by fasting glucose identified
a substantial prevalence of undetected type 2 diabetes
and IFG. But instead of an opportunistic approach,
they invited at-risk patients to screening clinics run by
trained practice nurses, and other risk factors like fam-
ily history of diabetes or hypertension were not con-
sidered. Nevertheless, the simple screening system they
describe—like ours—would promote an efficient use of
scarce primary care resources especially when part of
a broader cardiovascular disease reducing screening
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programme. Other studies concerning screening for type
2 diabetes mainly used questionnaires or risk scores to
identify at-risk patients, instead of data already present
in the EMR.10–12
Implications for clinical practice and future research
Although it was feasible to use the EMR in diabetes
screening, it was not valuable without additional risk
assessment and updating risk information during con-
sultation. Jordan et al.26 concluded in a recent system-
atic review concerning morbidity coding in the GP’s
EMR that a high quality of coding can be achieved,
although it is not yet clear which methods can en-
courage and help GPs to improve quality of coding.
Our study showed that 65% of the population con-
sulting the GP were at risk when applying the current
ADA recommendations. About the same figure (70%)
was found in the US National Health and Nutrition
Examination Survey.1 Although high percentages, we
would not recommend screening all middle-aged peo-
ple, for example, considering the possible consequences
of falsely positive test results, the burden of invasive
blood testing and costs of screening tests. Our figures
showed that 62% of those at risk have either hyperten-
sion or cardiovascular disease. The US Preventive Serv-
ices Task Force recommendations stress that patients at
increased risk for cardiovascular disease may benefit
most from screening for type 2 diabetes. Diabetes
screening should be part of an integrated approach to
reduce cardiovascular risk.5–8 If FPG measuring would
be a structural part of care in all patients with cardio-
vascular morbidity and hypertension, the number of
at-risk patients to be screened would be considerably
reduced. This emphasizes the importance of a system-
atic registration of overweight/obesity and family his-
tory of diabetes in primary care databases.
Conclusion
The GP’s EMR is an attractive tool for identifying at-
risk patients to initiate screening during usual care.
With additional risk assessment during consultation,
the GP’s EMR was valuable in identifying patients at
risk for undiagnosed type 2 diabetes. It was feasible to
use this information to initiate opportunistic screening.
Patients found to be at risk were highly willing to take
part in screening.
Better registration of family history of diabetes and
obesity will improve the EMR as a tool for identifying
at-risk patients in opportunistic screening in general
practice.
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